Study of LMY-922 CAR-T Cells for Blood Cancers
This study is testing a new type of cell therapy called LMY-922 (BAFF CAR-T cells) for people with certain blood cancers that have come back or not responded to other treatments. These cancers include Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Hairy Cell Leukemia, and Multiple Myeloma. LMY-922 is designed to target specific proteins on cancer cells, even if previous treatments like CD19 CAR-T cells didn't work. The main goals are to see how safe LMY-922 is and to find the best dose. You may be able to join if you are 18-75 years old and have one of these blood cancers that has relapsed after at least two other treatments. The study plans to enroll 27 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment (LMY-922). It aims to enroll 27 participants to assess safety and determine the best dose.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will assess safety and dose for 12 months.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- To assess the safety profile of LMY-922 in patients with refractory hematologic malignancies.12 Months
Incidence and severity of treatment-emergent adverse events
- To determine the Recommended Phase II Dose of LMY-922 in patients with refractory hematologic malignancies.12 Months
Incidence of dose limiting toxicities (DLT)